Peroxisome proliferator activated receptor-γ in pathogenesis of experimental fatty liver disease

World Journal of Gastroenterology

Volumn 10, Issue 9, 2004, Pages 1329-1332

  Zhao, Cai Yan ^a   Jiang, Ling Ling ^a   Li, Li ^a   Deng, Zhuo Jun ^a   Liang, Bao Li ^a   Li, Jian Mei ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; MALONALDEHYDE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG TARGETING; ELECTRON MICROSCOPY; FAT INTAKE; FATTY LIVER; FEMALE; HEPATITIS; HISTOCHEMISTRY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIVER FIBROSIS; LIVER HOMOGENATE; LIVER NECROSIS; LIVER STRUCTURE; NONHUMAN; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RANDOMIZATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 4444354099     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v10.i9.1329     Document Type: Article

References (32)

1. Day CP, James OF. Steatohepatitis: a tale of two "hits". Gastroenterology 1998; 114: 842-845
2. Chitturi S, George J. Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis. Curr Gastroenterol Rep 2003; 5: 18-25
3. Gao ZQ, Lu FE. Free fatty acid, insulin resistance and nonalcoholic steatohepatitis. Shijie Huaren Xiaohua Zazhi 2003; 11: 1043-1045
4. Fan JG. Steat ohepatitis studies. Shijie Huaren Xiaohua Zazhi 2001; 9: 6-10
5. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-379
6. Wu Q, Cheng J, Li L. Study on alcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2002; 10: 1037-1038
7. Bedoucha M, Atzpodien E, Boelsterli UA. Diabetic KKAY mice exhibit increased hepatic PPAR gamma 1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J Hepatol 2001; 35: 17-23
8. Kersten S. Peroxisome proliferator activated receptors and obesity. Eur J Pharmacol 2002; 440: 223-234
9. Clarke SD, Thuillier P, Baillie RA, Sha X. Peroxisome proliferator -activated receptors: a family of lipid-activated transcription factors. Am J Clin Nutr 1999; 70: 566-571
10. Kersten S, Mandard S, Escher P, Gonzalez FJ, Tafuri S, Desvergne B, Wahli W. The peroxisome proliferator-activated receptor alpha regulates amino acid metabolism. FASEB J 2001; 15: 1971-1978
11. Kon K, Ikejima K, Hirose M, Yoshikawa M, Enomoto N, Kitamura T, Takei K, Sato N. Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochem Biophys Res Commun 2002; 291: 55-61
12. Marra F, Efsen E, Romanelli RG, Caligiuri A, Pastacaldi S, Batignani G, Bonacchi A, Caporale R, Laffi G, Pinzani M, Gentilini P. Ligands of peroxisome proliferator -activated receptor gamma modulate profibrogenic ahd proinflammatory actions in hepatic stellate cells. Gastroenterology 2000; 119: 466-478
13. Li MY, Deng H, Zhao JM, Dai D, Tan XY. Peroxisome proliferator-activated receptor gamma ligands inhibit cell growth and induce apoptosis in human liver cancer BEL-7402 cells. World J Gastroenterol 2003; 9: 1683-1688
14. Li MY, Deng H, Zhao JM, Dai D, Tan XY. PPARgamma pathway activation results in apoptosis and COX-2 inhibition in HepG2 cells. World J Gastroenterol 2003; 9: 1220-1226
15. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000; 405: 421-424
16. Rao MS, Peters JM, Gonzalez FJ, Reddy JK. Hepatic regeneration in peroxisome proliferator-activated receptor alpha-null mice after partial hepatectomy. Hepatol Res 2002; 22: 52-57
17. Yu S, Rao S, Reddy JK. Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. Curr Mol Med 2003; 3: 561-572
18. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, - β, and -γ in the adult rat. Endocrinology 1996; 137: 354-366
19. Everett L, Galli A, Grabb D. The role of hepatic peroxisome proliferator -activated receptors (PPARs) in health and disease. Liver 2000; 20: 191-199
20. Reddy JK, Hashimoto T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu Rev Nutr 2001; 21: 193-230
21. Qi C, Zhu Y, Reddy JK. Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell Biochem Biophys 2000; 32: 187-204
22. Qi C, Zhu Y, Pan J, Usuda N, Maeda N, Yeldandi AV, Rao MS, Hashimoto T, Reddy JK. Absence of spontaneous peroxisome proliferation in enoyl-CoA Hydratase/L-3-hydroxyacyl-CoA dehydrogenase-deficient mouse liver. Further support for the role of fatty acyl CoA oxidase in PPARalpha ligand metabolism. J Biol Chem 1999; 274: 15775-15780
23. Yu S, Matsusue K, Kashireddy P, Cao WQ, Yeldandi V, Yeldandi AV, Rao MS, Gonzalez FJ, Reddy JK. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J Biol Chem 2003; 278: 498-505
24. Hashimoto T, Cook WS, Qi C, Yeldandi AV, Reddy JK, Rao MS. Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. J Biol Chem 2000; 275: 28918-28928
25. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 1999; 103: 1489-1498
26. Reddy JK. Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2001; 281: G1333-1339
27. Rao MS, Reddy JK. Peroxisomal beta-oxidation and steatohepatitis. Semin Liver Dis 2001; 21: 43-55
28. Fan CY, Pan J, Usuda N, Yeldandi AV, Rao MS. Reddy JK. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferaror-activated receptor alpha natural ligand metabolism. J Biol Chem 1998; 273: 15639-15645
29. Clarke SD. Nonalcoholic steatosis and steatohepatitis. I. Molecular mechanism for polyunsaturated fatty acid regulation of gene transcription. Am J Physiol Gastrointest Liver Physiol 2001; 281: G865-869
30. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001; 21: 27-41
31. Reginato MJ, Krakow SL, Bailey ST, Lazar MA. Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor gamma. J Biol Chem 1998; 273: 1855-1858
32. Miyahara T, Schrum L, Rippe R, Xiong S, Yee HF Jr, Motonura K, Anania FA, Willson TM, Tsukamoto H. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 2000; 275: 35715-35722